AstraZeneca Pharma India announced that Executive Director and CFO Bhavana Agrawal will resign as CFO on August 31, 2026 to take a regional role within the AstraZeneca Group, with a multi-week handover to ensure stability. For the fiscal year ended March 31, 2026, the company reported revenue of ₹22,755.80 million and a 33% year-on-year rise in revenue, alongside ongoing leadership succession planning as Agrawal departs from her executive roles. The move is framed as part of global corporate mobility within the AstraZeneca Group rather than a response to distress, and the company is conducting a formal search for a successor to maintain continuity. Regulatory filings confirm the resignation and note no disclosed shareholding or related-party relationships, with the specifics of the new regional role not disclosed in detail. This leadership transition keeps the group’s strategic realignment in view and investors will be watching how the change affects operations and governance. Market coverage indicates the change is being reported across multiple outlets, reflecting the significance of the CFO transition within AstraZeneca Pharma India.